Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Small cell lung cancer
What is your experience with the modified ramp-up of tarlatamab, where an extra 5 mg is given in the ramp-up phase before increasing to the full dose?
Related Questions
Can Dupixent and Durvalumab be used at the same time in a patient with extensive stage small cell lung cancer?
Is DLL3 expression necessary for tarlatamab efficacy in small cell lung cancer?
Would you switch from carboplatin/etoposide to cisplatin/etoposide in an LS-SCLC patient who initially declines cisplatin but subsequently agrees to it?
What are your top takeaways in Thoracic Cancers from ASCO 2025?
Does receipt of chemoimmunotherapy for LS-SCLC impact your recommendation for PCI?
Would you change systemic therapy in a patient with SCLC with stable systemic disease but CNS progression?
What are your top takeaways in thoracic cancers from ESMO 2025?
Would you offer tarlatamab to patients with metastatic EGFR+ NSCLC that transformed into SCLC?
Are you using maintenance lurbinectedin with immunotherapy in the first-line treatment of extensive stage small cell lung cancer?
How do you follow/manage patients with metastatic prostate cancer with undetectable PSA and castration-sensitive but active disease on PSMA PET?
